探讨Non-HDL-C、LP(a)与ACS患者冠脉狭窄程度的关系
To Explore the Relationship between Non-HDL-C and LP(a) and Coronary Stenosis in ACS Patients
DOI: 10.12677/ACM.2023.1351048, PDF,    科研立项经费支持
作者: 杨 倩:大理大学临床医学院,云南 大理;匡时权*:大理大学第一附属医院心内科,云南 大理
关键词: LP(a)Non-HDL-C冠状动脉狭窄程度急性冠脉综合征LP(a) Non-HDL-C Degree of Coronary Artery Stenosis Acute Coronary Syndrome
摘要: 目的:探究non-HDL-C、LP(a)与急性冠脉综合征患者冠脉病变严重程度的关系,为急性冠脉综合征患者的调脂策略提供思路。方法:选取2020年10月~2022年10月就诊于大理大学第一附属医院心血管内科诊断急性冠脉综合征并接受急诊冠状动脉造影手术的患者,收集纳入对象的临床资料。结果:冠状动脉极重度狭窄组的LDL-c、TG、TC、non-HDL-C、LP(a)水平较高。LP(a)、吸烟、糖尿病、高血压、non-HDL-C、LDL-c、BMI均为Gensini评分升高的独立危险因素。绘制ROC曲线发现,LP(a)、non-HDL-C预测冠状动脉重度狭窄的最佳截断值分别为21.25 mmol/l、3.645 mmol/l。结论:non-HDL-C、LP(a)是ACS患者冠脉狭窄程度的独立预测危险因素,其中LP(a)预测的特异性和敏感性较non-HDL-C强。
Abstract: Objective: To explore the relationship between non-HDL-C, LP(a) and the severity of coronary artery lesions in patients with acute coronary syndrome, and to provide ideas for the strategy of lipid reg-ulation in patients with acute coronary syndrome. Methods: Patients diagnosed with acute coronary syndrome and receiving emergency coronary angiography were selected from the Department of Cardiovascular Medicine of the First Affiliated Hospital of Dali University from October 2020 to Oc-tober 2022, and clinical data of the included subjects were collected. Results: The levels of LDL-c, TG, TC, non-HDL-C, LP(a) were higher in the extremely severe coronary artery stenosis group. LP(a), smoking, diabetes, hypertension, non-HDL-C, LDL-c and BMI were all independent risk factors for elevated Gensini score. ROC curve showed that the optimal cut-off values of LP(a) and non-HDL-C for predicting severe coronary artery stenosis were 21.25 mmol/l and 3.645 mmol/l, respectively. Conclusion: Non-HDL-C and LP(a) are independent risk factors for predicting the degree of coronary artery stenosis in patients with ACS, and the specificity and sensitivity of LP(a) are stronger than that of non-HDL-C.
文章引用:杨倩, 匡时权. 探讨Non-HDL-C、LP(a)与ACS患者冠脉狭窄程度的关系[J]. 临床医学进展, 2023, 13(5): 7506-7511. https://doi.org/10.12677/ACM.2023.1351048

参考文献

[1] Guilbert, J.J. (2003) The World Health Report 2002—Reducing Risks, Promoting Healthy Life. Education for Health (Abingdon), 16, 230. [Google Scholar] [CrossRef] [PubMed]
[2] Aggarwal, J., Reddy, S. and Nagtilak, S. (2016) Non-HDL-C: An Alternate to LDL-C for the Diagnosis of Cardiovascular Disease. IOSR Journal of Dental and Medical Sciences, 15, 1-4.
[3] Teramoto, T., Sasaki, J., Ishibashi, S., et al. (2013) Comprehensive Risk Management for the Prevention of Cardiovascular Disease: Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan—2012. Journal of Atherosclerosis and Thrombosis, 20, 603-615. [Google Scholar] [CrossRef] [PubMed]
[4] Sniderman, A.D., Williams, K., Contois, J.H., et al. (2011) A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. Circulation: Cardiovascular Quality and Outcomes, 4, 337-345. [Google Scholar] [CrossRef
[5] Nordestgaard, B.G. and Langsted, A. (2016) Lipo-protein(a) as a Cause of Cardiovascular Disease: Insights from Epidemiology, Genetics, and Biology. Journal of Lipid Research, 57, 1953-1975. [Google Scholar] [CrossRef
[6] Seki, R., Inoue, K., Yamamoto, S., et al. (2017) Non-HDL Cholesterol Is Better than Friedewald-Estimated LDL Cholesterol to Associate with Cardiometabolic Markers. Journal of BioMedical Research and Clinical Practice, 2, 1-6. [Google Scholar] [CrossRef
[7] Grundy, S.M., Stone, N.J., Bailey, A.L., et al. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1082-e1143. [Google Scholar] [CrossRef
[8] Arsenault, B.J. and Kamstrup, P.R. (2022) Lipoprotein (a) and Cardiovascular and Valvular Diseases: A Genetic Epidemiological Perspective. Atherosclerosis, 349, 7-16. [Google Scholar] [CrossRef] [PubMed]
[9] Utermann, G. (2006) Lipoprotein(a). In: Valle, D.L., Antonarakis, S., Ballabio, A., et al., Eds., The Online Metabolic and Molecular Bases of Inherited Disease (2001 Ed.), McGraw-Hill, New York.
[10] Langsted, A., Nordestgaard, B.G. and Kamstrup, P.R. (2019) Elevated Lipoprotein(a) and Risk of Ischemic Stroke. Journal of the American College of Cardiology, 74, 54-66. [Google Scholar] [CrossRef] [PubMed]
[11] Zheng, K.H., Tsimikas, S., Pawade, T., et al. (2019) Lipoprotein (a) and Oxidized Phospholipids Promote Valve Calcification in Patients with Aortic Stenosis. Journal of the American Col-lege of Cardiology, 73, 2150-2162. [Google Scholar] [CrossRef] [PubMed]
[12] Langsted, A., Kamstrup, P.R. and Nordestgaard, B.G. (2019) High Lipoprotein(a) and High Risk of Mortality. European Heart Journal, 40, 2760-2770. [Google Scholar] [CrossRef] [PubMed]
[13] Burgess, S., Ference, B.A., Staley, J.R., et al. (2018) Association of LPA Variants with Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiology, 3, 619-627. [Google Scholar] [CrossRef] [PubMed]